Table 2

Summary of Ipilimumab Trials

Trial

Patients

RR%

(CR/PR)

PFS (months)

OS

(years)

Number

(patients)

Summary


Phase 3

Hodi et al. [24]

Ipilimumab plus gp100

versus

Ipilimumab alone

versus

gp100 alone

previously treated metastatic melanoma

5.7

versus

10.9

versus

1.5

2.76

versus

2.86

versus

2.76

10.0

versus

10.1

versus

6.4

676

Ipilimumab with significant improvement in OS versus gp-100.

Phase 3

Robert et al. [23]

Ipilimumab plus dacarbazine

versus

dacarbazine in untreated metastatic melanoma

15.2

versus

10.3

Not stated

11.2

versus

9.1

502

Ipilimumab plus dacarbazine significantly with significant improvement in OS over dacarbazine.

Phase 2

Hersh et al. [40]

Ipilimumab

versus

Ipilimumab plus dacarbazine in chemotherapy naïve patients with metastatic melanoma

5.3

versus

14.3

Not stated

11.4

versus

14.4

72

Ipilimumab plus dacarbazine improved RR and OS compared to single agent ipilimumab.


CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response; RR, response rate.

Finn et al. BMC Medicine 2012 10:23   doi:10.1186/1741-7015-10-23

Open Data